Search company, investor...

Total Raised

$53.66M

Investors Count

13

Funding, Valuation & Revenue

5 Fundings

OxThera has raised $53.66M over 5 rounds.

OxThera's latest funding round was a Unattributed VC - III for $34.05M on November 29, 2016.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

11/29/2016

Unattributed VC - III

$34.05M

$99M

0

FY undefined

2

4/16/2014

Unattributed VC - II

$99M

$99M

0

FY undefined

10

9/25/2013

Grant

$99M

$99M

0

FY undefined

10

9/20/2012

Unattributed

$99M

$99M

0

FY undefined

10

6/30/2007

Unattributed VC

$99M

0

FY undefined

10

Date

11/29/2016

4/16/2014

9/25/2013

9/20/2012

6/30/2007

Round

Unattributed VC - III

Unattributed VC - II

Grant

Unattributed

Unattributed VC

Amount

$34.05M

$99M

$99M

$99M

Investors

Valuation

$99M

$99M

$99M

$99M

$99M

Revenue

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

Sources

2

10

10

10

10

You're one click away from the most comprehensive, unmatched analyst expertise in tech, in-depth private company data and a platform that brings it all together.
Click Now. Join a live demo
Join a demo
CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo

OxThera Investors

13 Investors

OxThera has 13 investors. Kurma Partners invested in OxThera's Unattributed VC - III funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

4/16/2014

11/29/2016

2
Unattributed VC - II, Unattributed VC - III (2016)

Venture Capital

France

4/16/2014

11/29/2016

2
Unattributed VC - II, Unattributed VC - III (2016)

Private Equity

France

6/30/2007

11/29/2016

2
Unattributed VC, Unattributed VC - III (2016)

Venture Capital

Sweden

00/00/0000

00/00/0000

Brohuvudet

Subscribe to see more

Venture Capital

Sweden

00/00/0000

00/00/0000

Sunstone Capital

Subscribe to see more

Venture Capital

Denmark

First funding

4/16/2014

4/16/2014

6/30/2007

00/00/0000

00/00/0000

Last Funding

11/29/2016

11/29/2016

11/29/2016

00/00/0000

00/00/0000

Investor

Brohuvudet

Sunstone Capital

Rounds

2
Unattributed VC - II, Unattributed VC - III (2016)
2
Unattributed VC - II, Unattributed VC - III (2016)
2
Unattributed VC, Unattributed VC - III (2016)

Subscribe to see more

Subscribe to see more

Board Seats

Type

Venture Capital

Private Equity

Venture Capital

Venture Capital

Venture Capital

Location

France

France

Sweden

Sweden

Denmark

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo

Compare OxThera to Competitors

A
Arcion Therapeutics

Arcion Therapeutics is a company with a focus on providing lifestyle-oriented content across various domains. The company offers a range of articles and guides on topics such as compact bike pumps, instant photo printing, vaping, jewelry sets, electric bikes, touch screen technology, mechanical bulls, home decor, textiles, and stationery. These offerings aim to inform and assist consumers in making lifestyle choices and engaging in DIY activities. It is based in Baltimore, Maryland.

E
EnzymeRx

EnzymeRx is a private, clinical stage biotechnology company developing uricase-PEG 20 for the treatment of resistant and refractory gout and related indications in which hyperuricemia plays a causative role.

A
AngioChem

AngioChem is a clinical-stage biotechnology company focused on developing pharmaceuticals for central nervous system diseases. The company specializes in creating Engineered Peptide Compounds (EPiC) that can cross the blood-brain barrier to treat a variety of brain diseases, including brain cancer, lysosomal storage disorders, and pain. AngioChem's products are designed to address medical needs that are currently unmet due to the challenges posed by the blood-brain barrier. It was founded in 2003 and is based in Montreal, Quebec.

E
Epeius Biotechnologies

Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.

Cerecin Logo
Cerecin

Cerecin is a healthcare company that focuses on brain health. The company develops a range of products including pharmaceuticals, medical foods, diagnostics, medical devices, and e-health products, all aimed at addressing conditions ranging from memory impairment to severe neurological diseases. Cerecin was formerly known as Accera. It was founded in 2001 and is based in Singapore, Singapore.

S
SpiderBiotech S.r.l.

Spider Biotech is a young and dynamic biotechnology company founded in 2005 with the aim of developing synthetic peptide therapeutics. nnAntimicrobial host-defense peptides have been recognized as an important part of innate immunity found throughout the evolutionary tree that defend against invading bacteria, viruses, and fungi through membrane or metabolic disruption. Inspired by natural antimicrobial peptides, Spider Biotech is developing a library of bioactive peptides and lipopeptides active against bacterial and viral infections. nSpiderBiotech's business strategy is to remain focused on the discovery and early-stage development of drug candidates and seek to establish partnerships with pharmaceutical companies for late-stage development and commercialization of its products. nnThe firm aims to become leader in developing peptide-based antiinfectives to address the urgent and global problem posed by resistance to conventional treatments. The Company is headquartered at the Bioindustry Park del Canavese (Turin, Italy).

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.